The report “ Global Malignant Peripheral Nerve Sheath Tumour Treatment Market, By Drugs (Ganetespib, CPI-0610, and Sirolimus) and Region – Global Forecast to 2029″ Global malignant peripheral nerve sheath tumour treatment market is projected to grow from US$ XX billion in 2019 to US$ XX billion by 2029. Increasing research and development on biological and targeted drug therapies for the malignant peripheral nerve sheath tumour is one of the major factors driving the growth of the global market. The global malignant peripheral nerve sheath tumour treatment market has further evolved due to the development of the new staging, imaging, and biopsy methods for the diagnosis of the malignant peripheral nerve sheath tumour hence increasing the opportunities for the treatment. However, high cost for the research and development for the treatment is restraining the growth of the global market.
- In November 2019, The Mayo Clinic has planned to develop a carbon ion treatment facility to fight cancer at its Jacksonville campus. Carbon ion therapy has the power to destroy cancer cells and tumors that are resistant to more traditional radiation therapy methods, without damaging surrounding tissue.
- In December 2019, University of Texas Southwestern Medical Center have built a software tool that uses artificial intelligence to identify cancer cells from digital pathology images – giving clinicians a powerful way of predicting patient outcomes.
- In April 2016, Synta and Madrigal announced merger agreement to create leading Cardiovascular-Metabolic Diseases and NASH Company. The merger will lead company to focus on the development of novel small-molecule drugs addressing major unmet needs in cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH).
Key Market Insights from the report:
The global malignant peripheral nerve sheath tumour treatment market accounted for US$ XX billion in 2019 and is projected to register a moderate CAGR of XX% over the forecast period. The market report has been segmented on the basis of drug, and region.
- By drug, the global malignant peripheral nerve sheath tumour treatment market is segmented into CPI-0610, ganetespib, and sirolimus.
Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “ Global Malignant Peripheral Nerve Sheath Tumor Treatment Market, By Drugs (Ganetespib, CPI-0610, and Sirolimus) and by Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa)- forecast till 2029
To know the upcoming trends and insights prevalent in this market, click the link below:
The prominent player operating in the global malignant peripheral nerve sheath tumour treatment market includes Mayo Clinic, University of Texas Southwestern Medical Center, Synta Pharmaceuticals Corp., and United States Department of Defense.